rs1799793 — ERCC2 D312N

ERCC2 D312N — A Second Hit to the DNA Repair Helicase

Your cells face thousands of DNA-damaging events every day. Ultraviolet radiation creates bulky pyrimidine dimers, tobacco smoke deposits polycyclic aromatic hydrocarbon adducts, and industrial chemicals leave behind covalent modifications that distort the double helix. The primary pathway for repairing all of these is nucleotide excision repair (NER)¹¹ nucleotide excision repair (NER)
the main DNA repair pathway for removing bulky adducts; it operates in two modes: global genome NER for damage anywhere in the genome, and transcription-coupled NER for lesions blocking active genes, and ERCC2 (also called XPD) is the helicase that makes it work.

ERCC2/XPD is a 5'-to-3' DNA helicase embedded in the ten-subunit TFIIH complex²² TFIIH complex
transcription factor IIH, a multiprotein machine required for both RNA polymerase II transcription initiation and nucleotide excision repair; mutations in its subunits cause xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. During NER, TFIIH unwinds approximately 30 base pairs of DNA around a lesion so that endonucleases can excise the damaged segment. The rs1799793 variant changes aspartic acid to asparagine at position 312 (D312N) in a conserved region of the helicase — reducing the precision of the repair machinery without disabling it entirely.

The Mechanism

The Asp312Asn substitution falls within the helicase domain of XPD, near motifs involved in ATP hydrolysis and DNA binding. Unlike the more C-terminal Lys751Gln variant (rs13181), which disrupts interaction with the CAK kinase subcomplex, the D312N change affects the catalytic core of the helicase itself. The functional consequence is measurable: a host-cell reactivation assay³³ host-cell reactivation assay
Spitz MR et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res, 2001 found that individuals homozygous for Asn312 had a 3.5-fold elevated risk of suboptimal DNA repair capacity (OR 3.50, 95% CI 1.06-11.59) compared to Asp/Asp carriers. This assay directly measures the cell's ability to repair a UV-damaged reporter plasmid — a functional readout of global NER efficiency.

Corroborating this, Hou et al. (2002)⁴⁴ Hou et al. (2002)
Hou SM et al. The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis, 2002 found that carriers of XPD variant alleles (including Asn312) accumulated significantly more aromatic DNA adducts in their peripheral blood lymphocytes (P=0.02), with the highest adduct burden in individuals carrying variant alleles at both exon 10 (Asp312Asn) and exon 23 (Lys751Gln) simultaneously. The adduct data provide direct biochemical evidence that the variant impairs the cell's ability to clear carcinogen-induced DNA damage.

The Evidence

Lung cancer. The largest meta-analysis covering rs1799793 and lung cancer, Zhan et al. (2010)⁵⁵ Zhan et al. (2010)
Zhan P et al. ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case-control studies. J Thorac Oncol, 2010, pooled 13,198 subjects and found that Asn/Asn homozygotes had significantly elevated lung cancer risk in the recessive model (OR 1.24, 95% CI 1.09-1.42). A subsequent meta-analysis by Feng et al. (2012)⁶⁶ meta-analysis by Feng et al. (2012)
Feng Z et al. Association of ERCC2/XPD polymorphisms and interaction with tobacco smoking in lung cancer susceptibility. Mol Biol Rep, 2012 confirmed the finding (homozygous OR 1.20, P=0.006) and reported an intriguing result: the risk elevation was especially pronounced among never-smokers in the dominant model, suggesting that even without heavy carcinogen exposure, the repair deficit manifests clinically over a lifetime.

Bladder cancer. A meta-analysis by Wang et al. (2009)⁷⁷ meta-analysis by Wang et al. (2009)
Wang M et al. XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis. J Toxicol Environ Health A, 2009 found Asn/Asn carriers at increased bladder cancer risk (OR 1.23, 95% CI 1.02-1.49 vs Asp/Asp), with the dominant model (any Asn allele) reaching OR 1.14 (95% CI 1.01-1.28). Notably, the Asp312Asn variant showed a stronger bladder cancer association than the Lys751Gln variant (rs13181), which did not reach significance for bladder cancer in the same analysis.

Overall cancer burden. The most comprehensive assessment, Xiao et al. (2017)⁸⁸ Xiao et al. (2017)
Xiao F et al. Association between the ERCC2 Asp312Asn polymorphism and risk of cancer. Oncotarget, 2017, combined 86 publications encompassing 38,848 cancer cases and 48,928 controls. The overall analysis confirmed a significant association between the Asp312Asn polymorphism and cancer risk, with the strongest signals for bladder, esophageal, and gastric cancers. The effect was most pronounced in Asian populations.

Smoking interaction. Multiple studies document a gene-environment interaction between XPD genotype and tobacco exposure. Smokers carrying the Asn312 allele accumulate carcinogen adducts faster and clear them more slowly, amplifying the mutagenic burden per pack-year compared to Asp/Asp smokers. The Hou et al. adduct study demonstrated this directly at the molecular level, while the meta-analyses show it epidemiologically through higher effect sizes in smoking-stratified subgroup analyses.

Practical Actions

The D312N variant operates through a dose-dependent mechanism: it does not cause cancer on its own, but it reduces the cellular repair buffer for bulky DNA adducts. This means the same carcinogen exposure produces more persistent DNA damage in Asn carriers than in Asp/Asp individuals. The highest-impact interventions are therefore exposure reduction (UV, tobacco smoke, environmental carcinogens) and support for the biochemical pathways that feed NER and protect against unrepaired oxidative damage.

Specific nutrients merit attention for carriers. Zinc is a structural cofactor for several NER proteins including XPD itself; ensuring adequate zinc status supports the repair complex. Selenium supports the glutathione peroxidase system that provides a secondary defense when NER falls short. And nicotinamide (vitamin B3) has been shown in a randomized controlled trial to reduce new non-melanoma skin cancers by 23% in high-risk individuals — an effect attributed in part to supporting NAD+-dependent DNA repair signaling through PARP enzymes.

Interactions

The most clinically relevant interaction is with rs13181 (ERCC2 Lys751Gln), the other well-characterized variant in the same gene. Both variants reduce NER capacity through different structural mechanisms — D312N affects the helicase catalytic core, while K751Q disrupts the CAK interface. Hou et al. found the highest DNA adduct levels in individuals carrying variant alleles at both positions, suggesting additive or synergistic impairment of repair. This within-gene interaction is documented at both the molecular (adduct accumulation) and epidemiological (cancer association) levels.

Interaction with XRCC1 (rs25487) is also relevant. XRCC1 participates in base excision repair (BER), a complementary DNA repair pathway. When NER is impaired by ERCC2 variants, BER provides a partial backup for certain types of oxidative DNA damage. Carriers of risk alleles at both ERCC2 and XRCC1 lose both primary and backup repair capacity — though published compound risk estimates for this specific combination are limited to candidate gene studies rather than large meta-analyses.

XPA (rs1800975) and ERCC1 are additional NER pathway genes whose variants could modify the net repair capacity. Multi-SNP risk scores combining multiple NER pathway variants are under investigation but not yet at actionable clinical evidence levels.